Barnes, Jill N.
Harvey, Ronée E.
Zuk, Samantha M.
Lundt, Emily S.
Lesnick, Timothy G.
Gunter, Jeffrey L.
Senjem, Matthew L.
Shuster, Lynne T.
Miller, Virginia M.
Jack, Clifford R. Jr.
Joyner, Michael J.
Kantarci, Kejal
Funding for this research was provided by:
National Institutes of Health (P50 AG044170, HL118154, HL83947, UL1 T000135)
Article History
Received: 31 January 2017
Revised: 13 March 2017
Accepted: 27 March 2017
First Online: 7 April 2017
Compliance with ethical standards
:
: Dr. Barnes is funded by NIH HL118154. Ms. Harvey, Ms. Zuk, Ms. Lundt, Mr. Lesnick, Dr. Gunter, Mr. Senjem do not report any disclosures. Dr. Shuster is funded by the NIH P50 AG44170. Dr. Miller is funded by the NIH P50 AG44170. Dr. Jack has provided consulting services for Eli Lilly Co. He receives research funding from the National Institutes of Health ((R01 AG011378, U01 HL096917, U01 AG024904, RO1 AG041851, R01 AG037551, R01 AG043392, U01 AG006786)) and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Foundation. Dr. Joyner is funded by NIH HL83947. Dr. Kantarci serves on the data safety monitoring board for Pfizer Inc., Takeda Global Research & Development Center, Inc.; and she is funded by the NIH [R01AG040042 (PI), R21 NS066147 (PI), Mayo Clinic Alzheimer’s Disease Research Center/Project 1 P50 AG16574/P1 (PI), P50 AG44170/Project 2 (PI) and R01 AG11378 (Co-I)].